Corporate Governance

Mr. Roman Kyrychynskyi, aged 49, was appointed as our independent non-executive Director in June 2023 with effect from the [REDACTED].

Mr. Kyrychynskyi joined AMD as group manager for planning and pricing from 2000 to 2005, and he subsequently served as a financial controller from 2007 to 2009. Mr. Kyrychynskyi later transitioned into the role of product director, senior director and vice president at AMD in 2009, 2018 and 2021 respectively, where he was responsible for conducting oversight of inventory and revenue management functions. In carrying out his roles at AMD since 2009, Mr. Kyrychynskyi was responsible for conducting valuations and setting standard costs of products. In addition, Mr. Kyrychynskyi was responsible for overseeing the revenue attainment workstream, which included setting business targets, and monitoring 
compliance with revenue recognition policies.

Mr. Kyrychynskyi is a Chartered Professional Accountants of Canada. Mr. Kyrychynskyi received his Bachelor of Commerce (Honours) at Queen’s University in  Canada in May 2000.

Ms. Denitsa Milanova, Ph.D., aged 40, was appointed as our independent non-executive Director in June 2023 with effect from the[REDACTED].

Ms. Milanova is a founder and chief executive officer of Medici Therapeutics, Inc. since October 2022. Prior to founding Medici, Ms. Milanova served as a Technology Development Fellow and Principal Investigator at Wyss Institute for Biologically Inspired Engineering of Harvard University from April 2018 to October 2022, and as a Postdoctoral Fellow in the Genetics Department of Harvard Medical School working with Prof. George Church from December 2015 to April 2018. Ms. Milanova also served as a business consultant at Ohana Biosciences (a subsidiary of Flagship Pioneering), a Boston-based life science company incubator, from April 2016 to November 2017.

Ms. Milanova became a Doctoral Fellow of the Stanford Microfluidics Laboratory under Prof. Juan Santiago at Stanford University School of Engineering in August 2008. In 2010, Ms. Milanova continued her degree while also collaborating with Profs. Annelise Barron in Molecular Bioengineering for Medicine and Biotechnology and Michael Snyder at Stanford University School of Medicine from January 2015 to January 2016. Prior to that, Ms. Milanova served as an undergraduate researcher at the Nanofluids and Two-Phase Flow Laboratory during her studies at University of Central Florida.

Ms. Milanova obtained a bachelor's degree in mechanical engineering from the University of Central Florida in the United States in May 2008.

Ms. Milanova received her Master's degree in Mechanical Engineering in June 2010, her Master's degree in Management Science and Engineering (an executive business degree focused on entrepreneurship) in June 2013, and her Ph.D. in Mechanical Engineering in January 2016 (all degrees from Stanford University in the United States). During her studies, Ms. Milanova was awarded a scholarship by the Graduate School of Engineering at Stanford University in 2008 and the Stanford Bio-X Medtronic Scholarship in 2011. Both scholarships provide comprehensive financial support for outstanding young researchers.

Mr. Jingsong Wang, Ph.D. (王勁松), aged 60, was appointed as our independent non-executive Director in June 2023 with effect from the [REDACTED].

Mr. Wang has served as an executive director, the chief executive officer and chairman of the board of HBM Holdings Limited, a company listed on the Hong Kong Stock Exchange (HKEx: 2142), since July 2016. Mr. Wang is the principal founder of HBM Holdings Limited. From November 2011 to December 2015, Mr. Wang served as the head of China research and development at Sanofi.

Mr. Wang has served as an independent non-executive director of Frontage Holdings Corporation, a company listed on the Hong Kong Stock Exchange (HKEx: 1521), since April 2018. Previously, he was an independent non-executive director of Xinjiang Bai Hua Cun Pharma Tech Co., Ltd. (新疆百花村醫藥集團股份有限公司), a company listed on the Shanghai Stock Exchange (SSE: 600721), from September 2021 to August 2024.

Mr. Wang received his M.D. in clinical medicine from Xuzhou Medical College in China in June 1986, his master’s degree in medical science (immunology) from Jilin University (formerly known as Norman Bethune University of Medical Science before the combination with Jilin University) in China in July 1989, and his Ph.D. in molecular pharmacology from China Pharmaceutical University in China in July 2011. Furthermore, Mr. Wang obtained the physician qualification granted by the Commonwealth of Massachusetts Board of Registration in Medicine in May 2002. Obtained the diploma of Internal Medicine and the Diploma of Rheumatology awarded by the American Board of Internal Medicine in 2003 and 2004 respectively. He obtained the certificates of internal Medicine and surgery from the State Board of Medicine of the Commonwealth of Pennsylvania in 2006. From June 2001 to June 2005, Mr. Wang served as a rheumatology research/clinical physician at Brigham and Women's Hospital and Harvard Medical School.